Abstract
More than 100 psychoactive drugs are available for the treatment of psychiatric disorders. However, remission rates are far from being optimal, as a significant number of patients poorly respond or are intolerant to many drugs. The fate of drugs in the organism depends on environmental (diet, smoking habits, comorbidities, comedications) and genetic factors. Therapeutic plasma level monitoring (TDM) of psychotropic drugs represents a useful tool for optimising pharmacotherapy. It is recommended in patients mentioned above, but also in situations of poor compliance, longterm treatment, in elderly and very young patients, and in somatically ill and comedicated patients. The introduction of phenotyping and genotyping procedures allows taking account of the pharmacogenetic status (e.g. cytochrome P–450, P-glycoprotein) of the patients not only for adjustment of their medication, but also for interpreting pharmacokinetic interactions with clinical consequences. In this respect, TDM and pharmacogenetic tests (phenotyping, genotyping) have now also to be considered as a tool in pharmacovigilance. Recently, the AGNP-TDM expert group published consensus guidelines for TDM of psychotropic drugs (Baumann et al., Pharmacopsychiatry 37: 243–265, 2004). In addition, recommendations on the optimal use of TDM in combination with pharmacogenetic tests in psychiatry were summarized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
